

ALGENICS receives grant to support development of its microalgal protein expression technology for the production of monoclonal antibodies in oncology

Saint-Herblain (FRANCE) - January 30, 2012 - Algenics, the biopharmaceutical company offering a unique microalgae-based solution for the development of recombinant biotherapeutics, announced that it has received a grant from OSEO, the French innovation agency, with the support of the European Regional Development Fund.

This grant, which is part of a €700 000 phase 1 project, will help support the establishment of an alternative and robust technology for manufacturing of monoclonal antibodies. The ongoing program aims at producing a biobetter of an antibody that has been successfully used in the treatment of various cancers. This second generation biotherapeutic will benefit from features of the microalgal cell line PTA to achieve enhanced biological properties while ensuring compliance with upstream & downstream processes suitable for secreted products into chemically-defined culture medium.

“This grant is fully in line with our strategy to extend our technology to therapeutic areas where we believe it can bring competitive advantage. This R&D program represents an important milestone for Algenics as it will both address the major market of monoclonal antibodies and will initiate the development of a product candidate” said Aude Carlier, CEO & CSO of Algenics.

About ALGENICS:

Algenics S.A.S is a privately-held biopharmaceutical company founded in 2008 and operating its own facility in Saint-Herblain /Nantes (FRANCE).

The company develops recombinant therapeutics for human health by leveraging a unique microalgae-based technology. Our platform *Algebiosys™* encompasses tools to efficiently generate stable strains of microalgal cells with high-level of safety. This proprietary and patented platform allows the biomanufacturing of a broad range of therapeutics including complex multimeric glycoproteins.

Our strategy is to develop biotherapeutics that benefit from our technologies. Our targets include recombinant products with enhanced biological activities for application in oncology and virology.

For more information please visit our website:

www.algenics.com

Contact:

Alexandre Lejeune

Business Development Manager

Algenics, Pôle Bio Ouest, rue du Moulin Rousselière

44800 Saint-Herblain, FRANCE

contact@algenics.com

T: +33 2 40 40 75 22 ; F: +33 2 40 59 32 44